Research

Aquis Stock Exchange: Application for admission to the AQSE Growth Market

Retrieved on: 
Monday, May 16, 2022 - 8:03am

The focus of the Psych Group will be to scale and grow the Psych Platform business, a business-to-business media and content platform for the psychedelic science and healthcare industry.

Key Points: 
  • The focus of the Psych Group will be to scale and grow the Psych Platform business, a business-to-business media and content platform for the psychedelic science and healthcare industry.
  • The Company also intends to seek opportunities to undertake additional buy and build investments into the medical psychedelic sector.
  • The Psych Platform is a global B2B resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events.
  • The Psych Platform has amassed a significant global B2B audience, with over 20,000 subscribers to the platform.

Grayscale Investments® Launches First European ETF: Grayscale Future of Finance UCITS ETF

Retrieved on: 
Monday, May 16, 2022 - 8:00am

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital currency asset manager, today announced its first European ETF, Grayscale Future of Finance UCITS ETF (ticker: GFOF), will list on the London Stock Exchange (LSE), Borsa Italiana, and Deutsche Börse Xetra. GFOF UCITS ETF will also be passported for sale across Europe.

Key Points: 
  • GFOF UCITS ETF was created in collaboration with HANetf, Europes first full services white label UCITS ETF issuer.
  • Please check with your broker or intermediary that the relevant Product is available in your jurisdiction and suitable for your investment profile.
  • HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern, and innovative exposures to European ETF investors.
  • Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

Digital Educational Publishing Market Size in Europe to Grow by USD 2.65 billion | 34% of Market Growth to Originate from UK | Technavio

Retrieved on: 
Monday, May 16, 2022 - 7:10am

The increasing number of international students enrolling in online degrees will facilitate the digital educational publishing market growth in the UK over the forecast period.

Key Points: 
  • The increasing number of international students enrolling in online degrees will facilitate the digital educational publishing market growth in the UK over the forecast period.
  • Key Market Drivers & Challenges:
    The innovative marketing strategies by digital education content publishers are driving the growth of the digital educational publishing market in Europe.
  • The high availability of open-source material will challenge the digital educational publishing market in Europe.
  • Thus, the rising popularity of MOOCs and open-source learning is expected to challenge the growth of the digital educational publishing market in Europe during the forecast period.

Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project

Retrieved on: 
Monday, May 16, 2022 - 7:02am

Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition get started 2gether organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize.

Key Points: 
  • Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition get started 2gether organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize.
  • Xsight Optics' vision is to expand human-centered, digital care.
  • The awarded prize money of EUR 80,000 will enable Xsight Optis to finance a corresponding R&D project with the Intelligent Systems Department of the Institute for Applied Building Research Weimar.
  • Oliver R. Baumann, CEO of Xlife Sciences, comments: We warmly congratulate CEO Maria Nisser and CSO Jan Sperrhake of our project company Xsight Optics for their doubly successful pitch at the renowned Thuringian StartUp funding award get started 2gether.

Inventiva secures a €50 million credit facility from the European Investment Bank

Retrieved on: 
Monday, May 16, 2022 - 7:00am

The facility is divided into two tranches of 25 million each.

Key Points: 
  • The facility is divided into two tranches of 25 million each.
  • The disbursement of the first tranche (Tranche A) is subject to the completion of certain conditions precedent specified in the credit facility agreement.
  • The maturity date of any borrowings under the facility is four years after disbursement of Tranche A and three years after disbursement of Tranche B.
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: We are very pleased with this credit facility, one of the largest granted by the EIB to a biotech.

SOM Biotech signs licensing agreement with the University of Minnesota

Retrieved on: 
Monday, May 16, 2022 - 7:00am

SOM Biotech (SOM or the Company), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a licensing agreement with the University of Minnesota.

Key Points: 
  • SOM Biotech (SOM or the Company), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a licensing agreement with the University of Minnesota.
  • The work under the SRA resulted in inventions covering nine potential product candidates, which SOM chose to license exclusively from the University of Minnesota.
  • SOM is currently conducting additional preclinical studies at the University of Minnesota to select the best potential candidates to take forward into development for Duchenne and Becker muscular dystrophy.
  • Ral Insa, Chief Executive Officer of SOM Biotech, said: This agreement with the University of Minnesota, a leading global research university, shows the exceptional value provided by our SOMAIPRO platform and its unique approach to AI-based drug discovery.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Retrieved on: 
Monday, May 16, 2022 - 6:30am

The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.

Key Points: 
  • The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGENs offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample.
  • The launch of QIAstat-Dx Rise syndromic testing platform provides automated, comprehensive pathogen testing for higher-demand medical institutions, said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN.
  • QIAstat-Dx Rise and its test cartridges are a closed system for hands-off sample preparation and processing.
  • Building on the existing QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx Rise is a flexible new option for increased testing capacity.

Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5

Retrieved on: 
Monday, May 16, 2022 - 7:00am

ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.

Key Points: 
  • ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
  • Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

PENSION FUND COALITION FOR INCLUSIVE CAPITALISM RELEASES RESOURCE TO FOCUS INVESTMENTS ON LONG-TERM VALUE CREATION

Retrieved on: 
Monday, May 16, 2022 - 5:01am

The Pension Fund Coalition for Inclusive Capitalism has developed model ESG impact contract language for use in asset owner agreements signed with asset managers, encompassing a range of approaches to pension fund investments in public and private equity markets.

Key Points: 
  • The Pension Fund Coalition for Inclusive Capitalism has developed model ESG impact contract language for use in asset owner agreements signed with asset managers, encompassing a range of approaches to pension fund investments in public and private equity markets.
  • The Pension Fund Coalition for Inclusive Capitalism, co-chaired by Theresa Whitmarsh and Hiro Mizuno, collaborated with public pension fund managers and legal advisors to provide pension funds and other asset owners a guide for structuring ESG impact provisions in investment agreements.
  • On May 18 at 12 p.m. EDT, the Coalition for Inclusive Capitalism will cohost a virtual event with CFA Society New York and CFA Society Seattle to discuss the work of the Pension Fund Coalition for Inclusive Capitalism.
  • Speakers will include pension fund managers and thought leaders, including Coalition for Inclusive Capitalism founder Lynn Forester de Rothschild and Pension Fund Coalition for Inclusive Capitalism co-chairs Theresa Whitmarsh and Hiro Mizuno.

LG Chem Develops Advanced Plastic Product to Prevent Thermal Runaway in EV Batteries

Retrieved on: 
Monday, May 16, 2022 - 6:00am

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220515005002/en/
    LG Chem has developed an advanced plastic product which prevents thermal runaway in EV batteries.
  • (Photo: Business Wire)
    LG Chems flame-retardant engineering plastic product is able to prevent the spread of flames, thanks to the companys proprietary technology and manufacturing methods.
  • The new advanced flame barrier product created by LG Chem is a highly functional engineering plastic product made from various composites including polyphenylene oxide (PPO) and polyamide (PA) resin.
  • Thermal runaway is the leading cause of EV battery fires, where various stressors can cause heat to build up within a battery cell.